{"protocolSection": {"identificationModule": {"nctId": "NCT00766090", "orgStudyIdInfo": {"id": "112202"}, "organization": {"fullName": "GlaxoSmithKline", "class": "INDUSTRY"}, "briefTitle": "Safety and Efficacy of GW685698X an Inhaled Corticosteroid Once Daily and Twice Daily for the Treatment of Asthma", "officialTitle": "A Multi-Centre, Randomized, Double Blind Cross-over Study to Assess the Non-inferiority of GW685698X 200mcg Once Daily and 100mcg Twice Daily in Adult and Adolescent Patients With Asthma"}, "statusModule": {"statusVerifiedDate": "2016-10", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-10"}, "primaryCompletionDateStruct": {"date": "2009-03", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-03", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-10-02", "studyFirstSubmitQcDate": "2008-10-02", "studyFirstPostDateStruct": {"date": "2008-10-03", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2013-06-06", "resultsFirstSubmitQcDate": "2013-06-06", "resultsFirstPostDateStruct": {"date": "2013-08-07", "type": "ESTIMATED"}, "dispFirstSubmitDate": "2010-02-05", "dispFirstSubmitQcDate": "2010-02-05", "dispFirstPostDateStruct": {"date": "2010-02-10", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-10-26", "lastUpdatePostDateStruct": {"date": "2016-12-08", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "GlaxoSmithKline", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to compare once and twice daily GW685698 in asthma"}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 190, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "GW685698X", "type": "EXPERIMENTAL", "interventionNames": ["Drug: GW685698X"]}], "interventions": [{"type": "DRUG", "name": "GW685698X", "description": "Inhaled Corticosteroid", "armGroupLabels": ["GW685698X"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Trough Forced Expiratory Volume in One Second (FEV1) at Day 28 of the Relevant Treatment Period", "description": "Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. FEV1 was measured electronically by spirometry. Trough FEV1 was the evening pre-dose, pre-rescue bronchodilator FEV1 measurement taken on Day 28 of the relevant treatment period. The analysis was performed using mixed model analysis of covarience (ANCOVA) with fixed effects of treatment, period, sex, and age. Participants were fitted as a random effect, and the period Baseline measurement was included as part of a bivariate response.", "timeFrame": "Day 28 of the relevant treatment period (up to Study Day 112)"}], "secondaryOutcomes": [{"measure": "Number of Participants With Any Adverse Event (AE) and Any Serious Adverse Event (SAE) Throughout the Three 28-day Treatment Periods", "description": "An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect. Medical or scientific judgment was exercised in deciding whether reporting was appropriate in other situations. Refer to the general AE/SAE module for a list of AEs (occuring at a frequency threshold \\>=3%) and SAEs.", "timeFrame": "From the first dose of the study medication up to Week 16/Early Withdrawal"}, {"measure": "24-hour Urinary Cortisol Excretion at Day 28 of the Relevant Treatment Period", "description": "A 24-hour urine sample was collected, and the 24-hour urinary cortisol excretion was analyzed at Day 28 of the relevant treatment period.", "timeFrame": "Day 28 of the relevant treatment period (up to Study Day 112)"}, {"measure": "Number of Participants With Evidence of Oropharyngeal Candidiasis at Day 0 and Day 28 of the Relevant Treatment Period", "description": "Detailed oropharyngeal examination for visual evidence of oropharyngeal candidiasis was performed at Day 0 (clinic visits 2, 4, and 6) and Day 28 (clinic visits 3, 5, and 7) of the relevant treatment period.", "timeFrame": "Day 0 and Day 28 of the relevant treatment period (up to Study Day 112)"}, {"measure": "Systolic and Diastolic Blood Pressure at Day 0 and Day 28 of the Relevant Treatment Period", "description": "Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured at Day 0 (clinic visits 2, 4, and 6) and Day 28 (clinic visits 3, 5, and 7) of the relevant treatment period.", "timeFrame": "Day 0 and Day 28 of the relevant treatment period (up to Study Day 112)"}, {"measure": "Heart Rate at Day 0 and Day 28 of the Relevant Treatment Period", "description": "Heart rate was measured at Day 0 (clinic visits 2, 4, and 6) and Day 28 (clinic visits 3, 5, and 7) of the relevant treatment period.", "timeFrame": "Day 0 and Day 28 of the relevant treatment period (up to Study Day 112)"}, {"measure": "Number of Participants Who Withdrew Due to Worsening of Asthma During the Three Treatment Periods", "description": "Participants were withdrawn from the study due to worsening of asthma (lack of efficacy) if they experienced a clinical asthma exacerbation or if clinic FEV1 fell below the FEV1 stability limit, or if during the 7 days immediately preceeding a visit the participant experienced either four or more days in which the PEF had fallen below the PEF stability limit or three or more days in which \\>=12 inhalations/day of albuterol/salbutamol were used. A clinical asthma exacerbation is defined as the worsening of asthma requiring emergency room visits, hospitalization, or treatment with an asthma medication (inhaled or systemic corticosteroids) other than study medication or rescue salbutamol/albuterol.", "timeFrame": "From the first dose of the study medication up to Week 16/Early Withdrawal"}]}, "eligibilityModule": {"eligibilityCriteria": "Key Inclusion Criteria:\n\n* Clinical diagnosis of Asthma\n* Reversibility \u2265 12% and \u2265200mls reversibility of FEV1 within approximately 30-minutes following 2 to 4 puffs of albuterol\n* FEV1 between 40-85% predicted\n* Currently on short acting beta2 agonist therapy\n\nKey Exclusion Criteria:\n\n* History of life threatening asthma\n* Respiratory Infection or oropharyngeal candidiasis\n* Asthma exacerbation\n* Uncontrolled disease or clinical abnormality\n* Allergies\n* Taking another Investigational medications or other prohibited medications", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "GSK Clinical Trials", "affiliation": "GlaxoSmithKline", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "GSK Investigational Site", "city": "Long Beach", "state": "California", "zip": "90806", "country": "United States", "geoPoint": {"lat": 33.76696, "lon": -118.18923}}, {"facility": "GSK Investigational Site", "city": "Long Beach", "state": "California", "zip": "90808", "country": "United States", "geoPoint": {"lat": 33.76696, "lon": -118.18923}}, {"facility": "GSK Investigational Site", "city": "Torrance", "state": "California", "zip": "90505", "country": "United States", "geoPoint": {"lat": 33.83585, "lon": -118.34063}}, {"facility": "GSK Investigational Site", "city": "Cocoa", "state": "Florida", "zip": "32927", "country": "United States", "geoPoint": {"lat": 28.38612, "lon": -80.742}}, {"facility": "GSK Investigational Site", "city": "Tallahassee", "state": "Florida", "zip": "32308", "country": "United States", "geoPoint": {"lat": 30.43826, "lon": -84.28073}}, {"facility": "GSK Investigational Site", "city": "Bethesda", "state": "Maryland", "zip": "20814", "country": "United States", "geoPoint": {"lat": 38.98067, "lon": -77.10026}}, {"facility": "GSK Investigational Site", "city": "Columbia", "state": "Missouri", "zip": "65203", "country": "United States", "geoPoint": {"lat": 38.95171, "lon": -92.33407}}, {"facility": "GSK Investigational Site", "city": "Rolla", "state": "Missouri", "zip": "65401", "country": "United States", "geoPoint": {"lat": 37.95143, "lon": -91.77127}}, {"facility": "GSK Investigational Site", "city": "Raleigh", "state": "North Carolina", "zip": "27607", "country": "United States", "geoPoint": {"lat": 35.7721, "lon": -78.63861}}, {"facility": "GSK Investigational Site", "city": "Canton", "state": "Ohio", "zip": "44718", "country": "United States", "geoPoint": {"lat": 40.79895, "lon": -81.37845}}, {"facility": "GSK Investigational Site", "city": "Medford", "state": "Oregon", "zip": "97504", "country": "United States", "geoPoint": {"lat": 42.32652, "lon": -122.87559}}, {"facility": "GSK Investigational Site", "city": "Orangeburg", "state": "South Carolina", "zip": "29118", "country": "United States", "geoPoint": {"lat": 33.49182, "lon": -80.85565}}, {"facility": "GSK Investigational Site", "city": "Austin", "state": "Texas", "zip": "78750", "country": "United States", "geoPoint": {"lat": 30.26715, "lon": -97.74306}}, {"facility": "GSK Investigational Site", "city": "Boerne", "state": "Texas", "zip": "78006", "country": "United States", "geoPoint": {"lat": 29.79466, "lon": -98.73197}}, {"facility": "GSK Investigational Site", "city": "San Antonio", "state": "Texas", "zip": "78229", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "GSK Investigational Site", "city": "Waco", "state": "Texas", "zip": "76712", "country": "United States", "geoPoint": {"lat": 31.54933, "lon": -97.14667}}]}, "referencesModule": {"references": [{"pmid": "22188590", "type": "BACKGROUND", "citation": "Woodcock A, Bleecker ER, Busse WW, Lotvall J, Snowise NG, Frith L, Jacques L, Haumann B, Bateman ED. Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma. Respir Res. 2011 Dec 21;12(1):160. doi: 10.1186/1465-9921-12-160."}, {"pmid": "27881132", "type": "DERIVED", "citation": "O'Byrne PM, Jacques L, Goldfrad C, Kwon N, Perrio M, Yates LJ, Busse WW. Integrated safety and efficacy analysis of once-daily fluticasone furoate for the treatment of asthma. Respir Res. 2016 Nov 24;17(1):157. doi: 10.1186/s12931-016-0473-x."}], "seeAlsoLinks": [{"label": "Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.", "url": "https://www.clinicalstudydatarequest.com"}], "availIpds": [{"id": "112202", "type": "Annotated Case Report Form", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "112202", "type": "Dataset Specification", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "112202", "type": "Study Protocol", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "112202", "type": "Informed Consent Form", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "112202", "type": "Statistical Analysis Plan", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "112202", "type": "Clinical Study Report", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "112202", "type": "Individual Participant Data Set", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site."}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Eligible participants (par.) at screening entered a 14-day Run-in Period. Par. were then randomized to 1 of 12 sequences: 6 had placebo and two doses of fluticasone furoate (FF), and 6 had placebo and two doses of fluticasone proprionate (FP) (allocation ratio of 7:2 \\[FF:FP\\]). 320 par. were screened and 190 were randomized.", "groups": [{"id": "FG000", "title": "Sequence 1: Placebo, FF 200 \u00b5g, FF 100 \u00b5g", "description": "Participants received placebo twice daily (BID), fluticasone furoate (FF) 200 microgram (\u00b5g) inhalation powder once daily (OD) in the evening, and FF 100 \u00b5g inhalation powder twice daily (BID) in Treatment Periods 1, 2, and 3, respectively. All treatments were administered via a Dry Powder Inhaler (DPI) for 28 days. Each of the 3 treatment periods was separated by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study."}, {"id": "FG001", "title": "Sequence 2: Placebo, FF 100 \u00b5g, FF 200 \u00b5g", "description": "Participants received placebo BID, FF 100 \u00b5g inhalation powder BID, and FF 200 \u00b5g inhalation powder OD in the evening in Treatment Periods 1, 2, and 3, respectively. All treatments were administered via a Dry Powder Inhaler (DPI) for 28 days. Each of the 3 treatment periods was separated by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study."}, {"id": "FG002", "title": "Sequence 3: FF 100 \u00b5g, Placebo, FF 200 \u00b5g", "description": "Participants received FF 100 \u00b5g inhalation powder BID, placebo BID, and FF 200 \u00b5g inhalation powder OD in the evening in Treatment Periods 1, 2, and 3, respectively. All treatments were administered via a Dry Powder Inhaler (DPI) for 28 days. Each of the 3 treatment periods was separated by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study."}, {"id": "FG003", "title": "Sequence 4: FF 100 \u00b5g, FF 200 \u00b5g, Placebo", "description": "Participants received FF 100 \u00b5g inhalation powder BID, FF 200 \u00b5g inhalation powder OD in the evening, and placebo BID in Treatment Periods 1, 2, and 3, respectively. All treatments were administered via a Dry Powder Inhaler (DPI) for 28 days. Each of the 3 treatment periods was separated by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study."}, {"id": "FG004", "title": "Sequence 5: FF 200 \u00b5g, Placebo, FF 100 \u00b5g", "description": "Participants received FF 200 \u00b5g inhalation powder OD in the evening, placebo BID, and FF 100 \u00b5g inhalation powder BID in Treatment Periods 1, 2, and 3, respectively. All treatments were administered via a Dry Powder Inhaler (DPI) for 28 days. Each of the 3 treatment periods was separated by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study."}, {"id": "FG005", "title": "Sequence 6: FF 200 \u00b5g, FF 100 \u00b5g, Placebo", "description": "Participants received FF 200 \u00b5g inhalation powder OD in the evening, FF 100 \u00b5g inhalation powder BID, and placebo BID in Treatment Periods 1, 2, and 3, respectively. All treatments were administered via a Dry Powder Inhaler (DPI) for 28 days. Each of the 3 treatment periods was separated by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study."}, {"id": "FG006", "title": "Sequence 7: Placebo, FP 200 \u00b5g, FP 100 \u00b5g", "description": "Participants received placebo twice daily (BID), fluticasone propionate (FP) 200 microgram (\u00b5g) inhalation powder once daily (OD) in the evening, and FP 100 \u00b5g inhalation powder twice daily (BID) in Treatment Periods 1, 2, and 3, respectively. All treatments were administered via a DISKUS inhaler for 28 days. Each of the 3 treatment periods was separated by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study."}, {"id": "FG007", "title": "Sequence 8: Placebo, FP 100 \u00b5g, FP 200 \u00b5g", "description": "Participants received placebo BID, FP 100 \u00b5g inhalation powder BID, and FP 200 \u00b5g inhalation powder OD in the evening in Treatment Periods 1, 2, and 3, respectively. All treatments were administered via a DISKUS inhaler for 28 days. Each of the 3 treatment periods was separated by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study."}, {"id": "FG008", "title": "Sequence 9: FP 100 \u00b5g, Placebo, FP 200 \u00b5g", "description": "Participants received FP 100 \u00b5g inhalation powder BID, placebo BID, and FP 200 \u00b5g inhalation powder OD in the evening in Treatment Periods 1, 2, and 3, respectively. All treatments were administered via a DISKUS inhaler for 28 days. Each of the 3 treatment periods was separated by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study."}, {"id": "FG009", "title": "Sequence 10: FP 100 \u00b5g, FP 200 \u00b5g, Placebo", "description": "Participants received FP 100 \u00b5g inhalation powder BID, FP 200 \u00b5g inhalation powder OD in the evening, and placebo BID in Treatment Periods 1, 2, and 3, respectively. All treatments were administered via a DISKUS inhaler for 28 days. Each of the 3 treatment periods was separated by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study."}, {"id": "FG010", "title": "Sequence 11: FP 200 \u00b5g, Placebo, FP 100 \u00b5g", "description": "Participants received FP 200 \u00b5g inhalation powder OD in the evening, placebo BID, and FP 100 \u00b5g inhalation powder BID in Treatment Periods 1, 2, and 3, respectively. All treatments were administered via a DISKUS inhaler for 28 days. Each of the 3 treatment periods was separated by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study."}, {"id": "FG011", "title": "Sequence 12: FP 200 \u00b5g, FP 100 \u00b5g, Placebo", "description": "Participants received FP 200 \u00b5g inhalation powder OD in the evening, FP 100 \u00b5g inhalation powder BID, and placebo BID in Treatment Periods 1, 2, and 3, respectively. All treatments were administered via a DISKUS inhaler for 28 days. Each of the 3 treatment periods was separated by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study."}], "periods": [{"title": "Treatment Period 1 (28 Days)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "25"}, {"groupId": "FG001", "numSubjects": "27"}, {"groupId": "FG002", "numSubjects": "23"}, {"groupId": "FG003", "numSubjects": "26"}, {"groupId": "FG004", "numSubjects": "23"}, {"groupId": "FG005", "numSubjects": "23"}, {"groupId": "FG006", "numSubjects": "6"}, {"groupId": "FG007", "numSubjects": "8"}, {"groupId": "FG008", "numSubjects": "7"}, {"groupId": "FG009", "numSubjects": "8"}, {"groupId": "FG010", "numSubjects": "7"}, {"groupId": "FG011", "numSubjects": "7"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "22"}, {"groupId": "FG001", "numSubjects": "27"}, {"groupId": "FG002", "numSubjects": "23"}, {"groupId": "FG003", "numSubjects": "25"}, {"groupId": "FG004", "numSubjects": "23"}, {"groupId": "FG005", "numSubjects": "23"}, {"groupId": "FG006", "numSubjects": "6"}, {"groupId": "FG007", "numSubjects": "8"}, {"groupId": "FG008", "numSubjects": "6"}, {"groupId": "FG009", "numSubjects": "8"}, {"groupId": "FG010", "numSubjects": "7"}, {"groupId": "FG011", "numSubjects": "7"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "1"}, {"groupId": "FG009", "numSubjects": "0"}, {"groupId": "FG010", "numSubjects": "0"}, {"groupId": "FG011", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "1"}, {"groupId": "FG009", "numSubjects": "0"}, {"groupId": "FG010", "numSubjects": "0"}, {"groupId": "FG011", "numSubjects": "0"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}, {"groupId": "FG010", "numSubjects": "0"}, {"groupId": "FG011", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}, {"groupId": "FG010", "numSubjects": "0"}, {"groupId": "FG011", "numSubjects": "0"}]}]}, {"title": "Washout Period 1 (14 Days)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "22"}, {"groupId": "FG001", "numSubjects": "27"}, {"groupId": "FG002", "numSubjects": "23"}, {"groupId": "FG003", "numSubjects": "25"}, {"groupId": "FG004", "numSubjects": "23"}, {"groupId": "FG005", "numSubjects": "23"}, {"groupId": "FG006", "numSubjects": "6"}, {"groupId": "FG007", "numSubjects": "8"}, {"groupId": "FG008", "numSubjects": "6"}, {"groupId": "FG009", "numSubjects": "8"}, {"groupId": "FG010", "numSubjects": "7"}, {"groupId": "FG011", "numSubjects": "7"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "22"}, {"groupId": "FG001", "numSubjects": "27"}, {"groupId": "FG002", "numSubjects": "22"}, {"groupId": "FG003", "numSubjects": "25"}, {"groupId": "FG004", "numSubjects": "23"}, {"groupId": "FG005", "numSubjects": "23"}, {"groupId": "FG006", "numSubjects": "6"}, {"groupId": "FG007", "numSubjects": "8"}, {"groupId": "FG008", "numSubjects": "6"}, {"groupId": "FG009", "numSubjects": "8"}, {"groupId": "FG010", "numSubjects": "7"}, {"groupId": "FG011", "numSubjects": "7"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}, {"groupId": "FG010", "numSubjects": "0"}, {"groupId": "FG011", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}, {"groupId": "FG010", "numSubjects": "0"}, {"groupId": "FG011", "numSubjects": "0"}]}]}, {"title": "Treatment Period 2 (28 Days)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "22"}, {"groupId": "FG001", "numSubjects": "27"}, {"groupId": "FG002", "numSubjects": "22"}, {"groupId": "FG003", "numSubjects": "25"}, {"groupId": "FG004", "numSubjects": "23"}, {"groupId": "FG005", "numSubjects": "23"}, {"groupId": "FG006", "numSubjects": "6"}, {"groupId": "FG007", "numSubjects": "8"}, {"groupId": "FG008", "numSubjects": "6"}, {"groupId": "FG009", "numSubjects": "8"}, {"groupId": "FG010", "numSubjects": "7"}, {"groupId": "FG011", "numSubjects": "7"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "22"}, {"groupId": "FG001", "numSubjects": "27"}, {"groupId": "FG002", "numSubjects": "21"}, {"groupId": "FG003", "numSubjects": "25"}, {"groupId": "FG004", "numSubjects": "21"}, {"groupId": "FG005", "numSubjects": "23"}, {"groupId": "FG006", "numSubjects": "6"}, {"groupId": "FG007", "numSubjects": "8"}, {"groupId": "FG008", "numSubjects": "6"}, {"groupId": "FG009", "numSubjects": "8"}, {"groupId": "FG010", "numSubjects": "7"}, {"groupId": "FG011", "numSubjects": "7"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "2"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}, {"groupId": "FG010", "numSubjects": "0"}, {"groupId": "FG011", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "2"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}, {"groupId": "FG010", "numSubjects": "0"}, {"groupId": "FG011", "numSubjects": "0"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}, {"groupId": "FG010", "numSubjects": "0"}, {"groupId": "FG011", "numSubjects": "0"}]}]}, {"title": "Washout Period 2 (14 Days)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "22"}, {"groupId": "FG001", "numSubjects": "27"}, {"groupId": "FG002", "numSubjects": "21"}, {"groupId": "FG003", "numSubjects": "25"}, {"groupId": "FG004", "numSubjects": "21"}, {"groupId": "FG005", "numSubjects": "23"}, {"groupId": "FG006", "numSubjects": "6"}, {"groupId": "FG007", "numSubjects": "8"}, {"groupId": "FG008", "numSubjects": "6"}, {"groupId": "FG009", "numSubjects": "8"}, {"groupId": "FG010", "numSubjects": "7"}, {"groupId": "FG011", "numSubjects": "7"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "22"}, {"groupId": "FG001", "numSubjects": "27"}, {"groupId": "FG002", "numSubjects": "20"}, {"groupId": "FG003", "numSubjects": "25"}, {"groupId": "FG004", "numSubjects": "21"}, {"groupId": "FG005", "numSubjects": "23"}, {"groupId": "FG006", "numSubjects": "6"}, {"groupId": "FG007", "numSubjects": "8"}, {"groupId": "FG008", "numSubjects": "6"}, {"groupId": "FG009", "numSubjects": "8"}, {"groupId": "FG010", "numSubjects": "7"}, {"groupId": "FG011", "numSubjects": "7"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}, {"groupId": "FG010", "numSubjects": "0"}, {"groupId": "FG011", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}, {"groupId": "FG010", "numSubjects": "0"}, {"groupId": "FG011", "numSubjects": "0"}]}]}, {"title": "Treatment Period 3 (28 Days)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "22"}, {"groupId": "FG001", "numSubjects": "27"}, {"groupId": "FG002", "numSubjects": "20"}, {"groupId": "FG003", "numSubjects": "25"}, {"groupId": "FG004", "numSubjects": "21"}, {"groupId": "FG005", "numSubjects": "23"}, {"groupId": "FG006", "numSubjects": "6"}, {"groupId": "FG007", "numSubjects": "8"}, {"groupId": "FG008", "numSubjects": "6"}, {"groupId": "FG009", "numSubjects": "8"}, {"groupId": "FG010", "numSubjects": "7"}, {"groupId": "FG011", "numSubjects": "7"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "22"}, {"groupId": "FG001", "numSubjects": "26"}, {"groupId": "FG002", "numSubjects": "20"}, {"groupId": "FG003", "numSubjects": "24"}, {"groupId": "FG004", "numSubjects": "20"}, {"groupId": "FG005", "numSubjects": "22"}, {"groupId": "FG006", "numSubjects": "6"}, {"groupId": "FG007", "numSubjects": "8"}, {"groupId": "FG008", "numSubjects": "6"}, {"groupId": "FG009", "numSubjects": "8"}, {"groupId": "FG010", "numSubjects": "7"}, {"groupId": "FG011", "numSubjects": "6"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "1"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}, {"groupId": "FG010", "numSubjects": "0"}, {"groupId": "FG011", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "1"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}, {"groupId": "FG010", "numSubjects": "0"}, {"groupId": "FG011", "numSubjects": "0"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}, {"groupId": "FG010", "numSubjects": "0"}, {"groupId": "FG011", "numSubjects": "1"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}, {"groupId": "FG010", "numSubjects": "0"}, {"groupId": "FG011", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "FF 200 \u00b5g, FF 100 \u00b5g, and Placebo Via DPI", "description": "Participants received FF 200 \u00b5g inhalation powder OD in the evening, FF 100 \u00b5g inhalation powder BID, and placebo BID in one of the three treatment periods. All treatments were administered via a Dry Powder Inhaler (DPI) for 28 days. Each of the 3 treatment periods was separated by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study."}, {"id": "BG001", "title": "FP 200 \u00b5g, FP 100 \u00b5g, and Placebo Via DISKUS", "description": "Participants received FP 200 \u00b5g inhalation powder OD in the evening, FP 100 \u00b5g inhalation powder BID, and placebo BID in one of the three treatment periods. All treatments were administered via a DISKUS for 28 days. Each of the 3 treatment periods was separated by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "147"}, {"groupId": "BG001", "value": "43"}, {"groupId": "BG002", "value": "190"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "31.4", "spread": "15.30"}, {"groupId": "BG001", "value": "35.2", "spread": "16.03"}, {"groupId": "BG002", "value": "32.3", "spread": "15.51"}]}]}]}, {"title": "Gender", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "87"}, {"groupId": "BG001", "value": "21"}, {"groupId": "BG002", "value": "108"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "60"}, {"groupId": "BG001", "value": "22"}, {"groupId": "BG002", "value": "82"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "African American/African Heritage (HER)", "categories": [{"measurements": [{"groupId": "BG000", "value": "50"}, {"groupId": "BG001", "value": "20"}, {"groupId": "BG002", "value": "70"}]}]}, {"title": "American Indian (AI) or Alaska Native (AN)", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}]}, {"title": "Japanese/East Asian HER/South East Asian HER", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "3"}]}]}, {"title": "Native Hawaiian or other Pacific Islander", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}]}, {"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "90"}, {"groupId": "BG001", "value": "22"}, {"groupId": "BG002", "value": "112"}]}]}, {"title": "African American/African HER & AI or AN & White", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}]}, {"title": "African American/African Heritage & White", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "2"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Trough Forced Expiratory Volume in One Second (FEV1) at Day 28 of the Relevant Treatment Period", "description": "Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. FEV1 was measured electronically by spirometry. Trough FEV1 was the evening pre-dose, pre-rescue bronchodilator FEV1 measurement taken on Day 28 of the relevant treatment period. The analysis was performed using mixed model analysis of covarience (ANCOVA) with fixed effects of treatment, period, sex, and age. Participants were fitted as a random effect, and the period Baseline measurement was included as part of a bivariate response.", "populationDescription": "Intent-to-Treat (ITT) Population: all participants randomized to treatment who received at least one dose of study medication", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters", "timeFrame": "Day 28 of the relevant treatment period (up to Study Day 112)", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo BID via the Dry Powder Inhaler (DPI) or the DISKUS inhaler for 28 days during one of the 3 treatment periods. Each treatment period was followed by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study."}, {"id": "OG001", "title": "FF 200 \u00b5g OD", "description": "Participants received FF 200 \u00b5g inhalation powder OD in the evening from the DPI for 28 days during one of the 3 treatment periods. Each treatment period was followed by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study."}, {"id": "OG002", "title": "FF 100 \u00b5g BID", "description": "Participants received FF 100 \u00b5g inhalation powder BID from the DPI for 28 days during one of the 3 treatment periods. Each treatment period was followed by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study."}, {"id": "OG003", "title": "FP 200 \u00b5g OD", "description": "Participants received FP 200 \u00b5g inhalation powder OD PM from the DISKUS inhaler for 28 days during one of the 3 treatment periods. Each treatment period was followed by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study."}, {"id": "OG004", "title": "FP 100 \u00b5g BID", "description": "Participants received FP 100 \u00b5g inhalation powder BID from the DISKUS inhaler for 28 days during one of the 3 treatment periods. Each treatment period was followed by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "187"}, {"groupId": "OG001", "value": "140"}, {"groupId": "OG002", "value": "142"}, {"groupId": "OG003", "value": "42"}, {"groupId": "OG004", "value": "43"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.605", "spread": "0.0434"}, {"groupId": "OG001", "value": "2.714", "spread": "0.0444"}, {"groupId": "OG002", "value": "2.703", "spread": "0.0443"}, {"groupId": "OG003", "value": "2.693", "spread": "0.0535"}, {"groupId": "OG004", "value": "2.737", "spread": "0.0533"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "0.108", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.064", "ciUpperLimit": "0.153"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "0.098", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.054", "ciUpperLimit": "0.142"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.020", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "0.087", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.014", "ciUpperLimit": "0.161"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Non-inferiority was demonstrated if the lower limit of the confidence interval (0.025, 1-sided significance level) for the mean difference in trough FEV1 of FF 200 \u00b5g OD versus FF 100 \u00b5g BID was greater than -110 milliliters.", "pValue": "0.641", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "0.011", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.035", "ciUpperLimit": "0.056"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "0.132", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.059", "ciUpperLimit": "0.205"}]}, {"type": "SECONDARY", "title": "Number of Participants With Any Adverse Event (AE) and Any Serious Adverse Event (SAE) Throughout the Three 28-day Treatment Periods", "description": "An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect. Medical or scientific judgment was exercised in deciding whether reporting was appropriate in other situations. Refer to the general AE/SAE module for a list of AEs (occuring at a frequency threshold \\>=3%) and SAEs.", "populationDescription": "ITT Population", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "From the first dose of the study medication up to Week 16/Early Withdrawal", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo BID via the Dry Powder Inhaler (DPI) or the DISKUS inhaler for 28 days during one of the 3 treatment periods. Each treatment period was followed by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study."}, {"id": "OG001", "title": "FF 200 \u00b5g OD", "description": "Participants received FF 200 \u00b5g inhalation powder OD in the evening from the DPI for 28 days during one of the 3 treatment periods. Each treatment period was followed by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study."}, {"id": "OG002", "title": "FF 100 \u00b5g BID", "description": "Participants received FF 100 \u00b5g inhalation powder BID from the DPI for 28 days during one of the 3 treatment periods. Each treatment period was followed by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study."}, {"id": "OG003", "title": "FP 200 \u00b5g OD", "description": "Participants received FP 200 \u00b5g inhalation powder OD PM from the DISKUS inhaler for 28 days during one of the 3 treatment periods. Each treatment period was followed by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study."}, {"id": "OG004", "title": "FP 100 \u00b5g BID", "description": "Participants received FP 100 \u00b5g inhalation powder BID from the DISKUS inhaler for 28 days during one of the 3 treatment periods. Each treatment period was followed by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "187"}, {"groupId": "OG001", "value": "140"}, {"groupId": "OG002", "value": "142"}, {"groupId": "OG003", "value": "42"}, {"groupId": "OG004", "value": "43"}]}], "classes": [{"title": "Any AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "2"}, {"groupId": "OG004", "value": "3"}]}]}, {"title": "Any SAE", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "24-hour Urinary Cortisol Excretion at Day 28 of the Relevant Treatment Period", "description": "A 24-hour urine sample was collected, and the 24-hour urinary cortisol excretion was analyzed at Day 28 of the relevant treatment period.", "populationDescription": "Urine Cortisol (UC) Population: participants who had both a Baseline urine sample and at least one urine sample from the end of a treatment period that did not have confounding factors that could affect the interpretation of results", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Nanomoles per 24 hours", "timeFrame": "Day 28 of the relevant treatment period (up to Study Day 112)", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo BID via the Dry Powder Inhaler (DPI) or the DISKUS inhaler for 28 days during one of the 3 treatment periods. Each treatment period was followed by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study."}, {"id": "OG001", "title": "FF 200 \u00b5g OD", "description": "Participants received FF 200 \u00b5g inhalation powder OD in the evening from the DPI for 28 days during one of the 3 treatment periods. Each treatment period was followed by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study."}, {"id": "OG002", "title": "FF 100 \u00b5g BID", "description": "Participants received FF 100 \u00b5g inhalation powder BID from the DPI for 28 days during one of the 3 treatment periods. Each treatment period was followed by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study."}, {"id": "OG003", "title": "FP 200 \u00b5g OD", "description": "Participants received FP 200 \u00b5g inhalation powder OD PM from the DISKUS inhaler for 28 days during one of the 3 treatment periods. Each treatment period was followed by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study."}, {"id": "OG004", "title": "FP 100 \u00b5g BID", "description": "Participants received FP 100 \u00b5g inhalation powder BID from the DISKUS inhaler for 28 days during one of the 3 treatment periods. Each treatment period was followed by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "153"}, {"groupId": "OG001", "value": "118"}, {"groupId": "OG002", "value": "116"}, {"groupId": "OG003", "value": "35"}, {"groupId": "OG004", "value": "39"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "53.94", "spread": "66.423"}, {"groupId": "OG001", "value": "40.25", "spread": "92.316"}, {"groupId": "OG002", "value": "45.13", "spread": "87.181"}, {"groupId": "OG003", "value": "56.16", "spread": "94.259"}, {"groupId": "OG004", "value": "47.56", "spread": "84.896"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Evidence of Oropharyngeal Candidiasis at Day 0 and Day 28 of the Relevant Treatment Period", "description": "Detailed oropharyngeal examination for visual evidence of oropharyngeal candidiasis was performed at Day 0 (clinic visits 2, 4, and 6) and Day 28 (clinic visits 3, 5, and 7) of the relevant treatment period.", "populationDescription": "ITT Population. Only those participants available at the specified time points were analyzed.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Day 0 and Day 28 of the relevant treatment period (up to Study Day 112)", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo BID via the Dry Powder Inhaler (DPI) or the DISKUS inhaler for 28 days during one of the 3 treatment periods. Each treatment period was followed by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study."}, {"id": "OG001", "title": "FF 200 \u00b5g OD", "description": "Participants received FF 200 \u00b5g inhalation powder OD in the evening from the DPI for 28 days during one of the 3 treatment periods. Each treatment period was followed by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study."}, {"id": "OG002", "title": "FF 100 \u00b5g BID", "description": "Participants received FF 100 \u00b5g inhalation powder BID from the DPI for 28 days during one of the 3 treatment periods. Each treatment period was followed by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study."}, {"id": "OG003", "title": "FP 200 \u00b5g OD", "description": "Participants received FP 200 \u00b5g inhalation powder OD PM from the DISKUS inhaler for 28 days during one of the 3 treatment periods. Each treatment period was followed by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study."}, {"id": "OG004", "title": "FP 100 \u00b5g BID", "description": "Participants received FP 100 \u00b5g inhalation powder BID from the DISKUS inhaler for 28 days during one of the 3 treatment periods. Each treatment period was followed by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "187"}, {"groupId": "OG001", "value": "140"}, {"groupId": "OG002", "value": "142"}, {"groupId": "OG003", "value": "42"}, {"groupId": "OG004", "value": "43"}]}], "classes": [{"title": "Day 0: Yes, n=187, 140, 142, 42, 43", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}]}, {"title": "Day 0: No, n=187, 140, 142, 42, 43", "categories": [{"measurements": [{"groupId": "OG000", "value": "187"}, {"groupId": "OG001", "value": "140"}, {"groupId": "OG002", "value": "142"}, {"groupId": "OG003", "value": "42"}, {"groupId": "OG004", "value": "43"}]}]}, {"title": "Day 28: Yes, n=178, 139, 140, 42, 42", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}]}, {"title": "Day 28: No, n=178, 139, 140, 42, 42", "categories": [{"measurements": [{"groupId": "OG000", "value": "178"}, {"groupId": "OG001", "value": "139"}, {"groupId": "OG002", "value": "140"}, {"groupId": "OG003", "value": "42"}, {"groupId": "OG004", "value": "42"}]}]}]}, {"type": "SECONDARY", "title": "Systolic and Diastolic Blood Pressure at Day 0 and Day 28 of the Relevant Treatment Period", "description": "Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured at Day 0 (clinic visits 2, 4, and 6) and Day 28 (clinic visits 3, 5, and 7) of the relevant treatment period.", "populationDescription": "ITT Population. Only those participants available at the specified time points were analyzed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "millimeters of mercury (mmHg)", "timeFrame": "Day 0 and Day 28 of the relevant treatment period (up to Study Day 112)", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo BID via the Dry Powder Inhaler (DPI) or the DISKUS inhaler for 28 days during one of the 3 treatment periods. Each treatment period was followed by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study."}, {"id": "OG001", "title": "FF 200 \u00b5g OD", "description": "Participants received FF 200 \u00b5g inhalation powder OD in the evening from the DPI for 28 days during one of the 3 treatment periods. Each treatment period was followed by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study."}, {"id": "OG002", "title": "FF 100 \u00b5g BID", "description": "Participants received FF 100 \u00b5g inhalation powder BID from the DPI for 28 days during one of the 3 treatment periods. Each treatment period was followed by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study."}, {"id": "OG003", "title": "FP 200 \u00b5g OD", "description": "Participants received FP 200 \u00b5g inhalation powder OD PM from the DISKUS inhaler for 28 days during one of the 3 treatment periods. Each treatment period was followed by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study."}, {"id": "OG004", "title": "FP 100 \u00b5g BID", "description": "Participants received FP 100 \u00b5g inhalation powder BID from the DISKUS inhaler for 28 days during one of the 3 treatment periods. Each treatment period was followed by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "187"}, {"groupId": "OG001", "value": "140"}, {"groupId": "OG002", "value": "142"}, {"groupId": "OG003", "value": "42"}, {"groupId": "OG004", "value": "43"}]}], "classes": [{"title": "SBP: Day 0, n=187, 140, 142, 42, 43", "categories": [{"measurements": [{"groupId": "OG000", "value": "120.1", "spread": "12.08"}, {"groupId": "OG001", "value": "118.3", "spread": "11.96"}, {"groupId": "OG002", "value": "119.5", "spread": "12.28"}, {"groupId": "OG003", "value": "122.1", "spread": "13.55"}, {"groupId": "OG004", "value": "121.3", "spread": "12.10"}]}]}, {"title": "SBP: Day 28, n=178, 139, 140, 42, 42", "categories": [{"measurements": [{"groupId": "OG000", "value": "119.6", "spread": "12.76"}, {"groupId": "OG001", "value": "120.5", "spread": "13.31"}, {"groupId": "OG002", "value": "120.6", "spread": "12.71"}, {"groupId": "OG003", "value": "120.4", "spread": "11.92"}, {"groupId": "OG004", "value": "120.1", "spread": "10.58"}]}]}, {"title": "DBP: Day 0, n=187, 140, 142, 42, 43", "categories": [{"measurements": [{"groupId": "OG000", "value": "75.8", "spread": "8.26"}, {"groupId": "OG001", "value": "74.6", "spread": "7.69"}, {"groupId": "OG002", "value": "76.0", "spread": "8.03"}, {"groupId": "OG003", "value": "77.5", "spread": "9.98"}, {"groupId": "OG004", "value": "76.6", "spread": "8.73"}]}]}, {"title": "DBP: Day 28, n=178, 139, 140, 42, 42", "categories": [{"measurements": [{"groupId": "OG000", "value": "75.8", "spread": "8.45"}, {"groupId": "OG001", "value": "74.9", "spread": "8.12"}, {"groupId": "OG002", "value": "76.4", "spread": "7.97"}, {"groupId": "OG003", "value": "76.0", "spread": "7.81"}, {"groupId": "OG004", "value": "75.7", "spread": "8.90"}]}]}]}, {"type": "SECONDARY", "title": "Heart Rate at Day 0 and Day 28 of the Relevant Treatment Period", "description": "Heart rate was measured at Day 0 (clinic visits 2, 4, and 6) and Day 28 (clinic visits 3, 5, and 7) of the relevant treatment period.", "populationDescription": "ITT Population. Only those participants available at the specified time points were analyzed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "beats per minute", "timeFrame": "Day 0 and Day 28 of the relevant treatment period (up to Study Day 112)", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo BID via the Dry Powder Inhaler (DPI) or the DISKUS inhaler for 28 days during one of the 3 treatment periods. Each treatment period was followed by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study."}, {"id": "OG001", "title": "FF 200 \u00b5g OD", "description": "Participants received FF 200 \u00b5g inhalation powder OD in the evening from the DPI for 28 days during one of the 3 treatment periods. Each treatment period was followed by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study."}, {"id": "OG002", "title": "FF 100 \u00b5g BID", "description": "Participants received FF 100 \u00b5g inhalation powder BID from the DPI for 28 days during one of the 3 treatment periods. Each treatment period was followed by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study."}, {"id": "OG003", "title": "FP 200 \u00b5g OD", "description": "Participants received FP 200 \u00b5g inhalation powder OD PM from the DISKUS inhaler for 28 days during one of the 3 treatment periods. Each treatment period was followed by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study."}, {"id": "OG004", "title": "FP 100 \u00b5g BID", "description": "Participants received FP 100 \u00b5g inhalation powder BID from the DISKUS inhaler for 28 days during one of the 3 treatment periods. Each treatment period was followed by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "187"}, {"groupId": "OG001", "value": "140"}, {"groupId": "OG002", "value": "142"}, {"groupId": "OG003", "value": "42"}, {"groupId": "OG004", "value": "43"}]}], "classes": [{"title": "Day 0, n=187, 140, 142, 42, 43", "categories": [{"measurements": [{"groupId": "OG000", "value": "77.0", "spread": "9.53"}, {"groupId": "OG001", "value": "76.4", "spread": "9.27"}, {"groupId": "OG002", "value": "77.6", "spread": "8.71"}, {"groupId": "OG003", "value": "74.5", "spread": "9.22"}, {"groupId": "OG004", "value": "75.8", "spread": "8.12"}]}]}, {"title": "Day 28, n=178, 139, 140, 42, 42", "categories": [{"measurements": [{"groupId": "OG000", "value": "76.6", "spread": "8.79"}, {"groupId": "OG001", "value": "76.9", "spread": "9.32"}, {"groupId": "OG002", "value": "77.7", "spread": "9.47"}, {"groupId": "OG003", "value": "74.7", "spread": "7.96"}, {"groupId": "OG004", "value": "74.6", "spread": "8.49"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Who Withdrew Due to Worsening of Asthma During the Three Treatment Periods", "description": "Participants were withdrawn from the study due to worsening of asthma (lack of efficacy) if they experienced a clinical asthma exacerbation or if clinic FEV1 fell below the FEV1 stability limit, or if during the 7 days immediately preceeding a visit the participant experienced either four or more days in which the PEF had fallen below the PEF stability limit or three or more days in which \\>=12 inhalations/day of albuterol/salbutamol were used. A clinical asthma exacerbation is defined as the worsening of asthma requiring emergency room visits, hospitalization, or treatment with an asthma medication (inhaled or systemic corticosteroids) other than study medication or rescue salbutamol/albuterol.", "populationDescription": "ITT Population", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "From the first dose of the study medication up to Week 16/Early Withdrawal", "groups": [{"id": "OG000", "title": "FF 200 \u00b5g, FF 100 \u00b5g, and Placebo Via DPI", "description": "Participants received FF 200 \u00b5g inhalation powder OD in the evening, FF 100 \u00b5g inhalation powder BID, and placebo BID in one of the three treatment periods. All treatments were administered via a Dry Powder Inhaler (DPI) for 28 days. Each of the 3 treatment periods was separated by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study."}, {"id": "OG001", "title": "FP 200 \u00b5g, FP 100 \u00b5g, and Placebo Via DISKUS", "description": "Participants received FP 200 \u00b5g inhalation powder OD in the evening, FP 100 \u00b5g inhalation powder BID, and placebo BID in one of the three treatment periods. All treatments were administered via a DISKUS for 28 days. Each of the 3 treatment periods was separated by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "147"}, {"groupId": "OG001", "value": "43"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "1"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "3", "timeFrame": "Serious adverse events (SAEs) and non-serious AEs were collected from the first dose of the study medication up to Week 16/Early Withdrawal.", "description": "SAEs and non-serious AEs were reported for members of the Intent-to-Treat (ITT) Population, comprised of all participants randomized to treatment who received at least one dose of study medication.", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Participants received placebo BID via the Dry Powder Inhaler (DPI) or the DISKUS inhaler for 28 days during one of the 3 treatment periods. Each treatment period was followed by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study.", "seriousNumAffected": 0, "seriousNumAtRisk": 187, "otherNumAffected": 2, "otherNumAtRisk": 187}, {"id": "EG001", "title": "FF 200 \u00b5g OD", "description": "Participants received FF 200 \u00b5g inhalation powder OD in the evening from the DPI for 28 days during one of the 3 treatment periods. Each treatment period was followed by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study.", "seriousNumAffected": 0, "seriousNumAtRisk": 140, "otherNumAffected": 7, "otherNumAtRisk": 140}, {"id": "EG002", "title": "FF 100 \u00b5g BID", "description": "Participants received FF 100 \u00b5g inhalation powder BID from the DPI for 28 days during one of the 3 treatment periods. Each treatment period was followed by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study.", "seriousNumAffected": 0, "seriousNumAtRisk": 142, "otherNumAffected": 7, "otherNumAtRisk": 142}, {"id": "EG003", "title": "FP 200 \u00b5g OD", "description": "Participants received FP 200 \u00b5g inhalation powder OD PM from the DISKUS inhaler for 28 days during one of the 3 treatment periods. Each treatment period was followed by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study.", "seriousNumAffected": 0, "seriousNumAtRisk": 42, "otherNumAffected": 0, "otherNumAtRisk": 42}, {"id": "EG004", "title": "FP 100 \u00b5g BID", "description": "Participants received FP 100 \u00b5g inhalation powder BID from the DISKUS inhaler for 28 days during one of the 3 treatment periods. Each treatment period was followed by a washout period of 14 days. Participants were provided supplemental albuterol/salbutamol (inhalation aerosol) to be used as needed throughout the study.", "seriousNumAffected": 0, "seriousNumAtRisk": 43, "otherNumAffected": 0, "otherNumAtRisk": 43}], "otherEvents": [{"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 187}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 140}, {"groupId": "EG002", "numAffected": 7, "numAtRisk": 142}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 42}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 43}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "GSK Response Center", "organization": "GlaxoSmithKline", "phone": "866-435-7343"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "T4202", "name": "Oculocerebral Syndrome With Hypopigmentation", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}}, "hasResults": true}